Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DepoCyte for central nervous system relapse in adults with acute lymphoblastic leukemia or highly aggressive lymphoma
2004-004414-17Phase 2Active
- Sponsor
- Fundación PETHEMA
- Start
- Sep 2005
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of liposomal cytarabine in acute lymphoblastic leukemia (ALL), Burkitt lymphoma (BL) and non-Hodgkin lymphoma (NHL), sponsored by Fundación PETHEMA. Primary endpoint: Response rate after a single administration of DepoCyte. Started Sep 2005; status: active.
02
Drugs
liposomal cytarabine
03
Conditions
acute lymphoblastic leukemia (ALL)Burkitt lymphoma (BL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on 2004-004414-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004414-17.